🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Evaluation of Memantine in the Preservation of Memory and Neurocognition Following CSI

RecruitingPhase 3Ages 5 Years - 39 YearsAllTata Memorial Centre
NCT06275035 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The goal of this clinical trial is to evaluate the role of memantine in preservation of memory and neurocognition in patients undergoing craniospinal irradiation. Participants will be randomised into two arms and the interventional arm will receive memantine along with the standard treatment. Researchers will compare the neurocognitive tests of participants in both the arms to see if memantine leads to significant preservation of memory and cognition post radiation therapy.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Age at irradiation: 5 to 39 years * Planned for CSI (with or without boost dose) with or without systemic chemotherapy * Informed consent or assent taken * Karnofsky Performance Status / Lansky Performance Status ≥ 60 Exclusion Criteria: * Re-irradiation * Prior exposure to memantine * Inability to undergo Wechsler test
💊

What it tests

  • Memantine Oral Tablet
📍

Where

1 site
Tata Memorial Hospital
Mumbai, India
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy